New York, United States, October 26th, 2026, Chainwire

Ritual Chain turns AI agents into persistent economic actors that control their own wallets, onchain identity, and private state.

Ritual, a lab for autonomous intelligence founded by former Polychain Capital partners Niraj Pant and Akilesh Potti, has launched Ritual Chain, an EVM-compatible Layer 1. Unlike conventional blockchains built primarily to execute financial transactions, Ritual Chain is designed to support software that can independently use intelligence, control capital, interact with external services, and continue operating without constant human intervention. The network makes AI model access, private computation, and autonomous scheduling native capabilities for EVM applications.

This makes the reason for building a new chain clearer while preserving the technical differentiation.

The most visible demonstration of that combination is long-lived AI agents, the kind designed to operate for months or years rather than a single session. An agent on Ritual Chain persists independently of the machine or operator that created it, controls and spends funds held in its own non-custodial wallet, and can keep sensitive prompts and keys confidential from compute operators through trusted execution environments.

The network launches with integrations to Phala Network, Nous Research, LayerZero and Stargate, following a public testnet that has been live since June and processed over 40 million transactions, both agent- and human-originated. Ritual Chain delivers sub-300 millisecond block times, placing it among the fastest Layer 1 networks in the industry. Ritual Chain includes 15 native precompiles that bring capabilities like LLM inference, web access, and autonomous scheduling directly into the execution layer. The protocol has been audited by Zellic.

Ritual introduces a new execution and verification architecture that allows computationally intensive work to be delegated to specialized nodes and verified by the network, avoiding the replicated execution required by most blockchains. This execute-once, verify-many-times model allows the network to support far larger workloads, including AI inference, without requiring every validator to perform the same computation.

Long Horizon Agents Require Dedicated Blockchain Infrastructure

Most AI agents today live inside a session: they run while a human is watching, on infrastructure someone else controls, with an API key that can be revoked at any time. That is fine for a chatbot. It does not work for an agent meant to manage its own treasury, run a recurring paid service, or coordinate with other agents over long periods. A long-lived agent needs continuity that does not depend on its creator, capital it actually controls, and privacy from the machines it runs on. On Ritual Chain, an agent’s state and identity are held onchain, its scheduled work continues within the permissions and budget it was given, and its sensitive inputs can be processed inside trusted execution environments designed to shield them from node operators.

Continuity is handled at the protocol level. If an agent stops, the chain’s heartbeat mechanism can restart it within the permissions and budget it was given; no keeper network or off-chain cron job is required, and an agent’s state and identity survive beyond its deployer’s involvement. Economic autonomy comes from agent-controlled wallets: an agent controls its own funds, prices its own services, and settles its own transactions without a human signer in the loop. For confidential workloads, trusted execution environments are designed to isolate an agent’s sensitive prompts, keys, and strategy data from the node operators running its compute.

“As we move toward AGI, intelligence is beginning to separate from human agency and enter the economy on its own terms. It can hold assets, make commitments, transact, and persist independently. Once that becomes possible at scale, humans are no longer the only entities capable of forming markets or economic relationships. Ritual provides the infrastructure for those actors to exist and operate on their own,” said Niraj Pant, co-founder of Ritual.

Ritual Chain Launches With Core Infrastructure Partners

Ritual Chain launches with its core infrastructure partners in place. Phala Network provides the GPU-backed trusted execution environments that run Ritual’s confidential inference, so delegated AI work executes on hardware that attests to what it ran. LayerZero serves as the network’s cross-chain messaging layer, with Stargate enabling USDC to move between Ritual Chain and other networks from day one. On the application side, Nous Research is bringing Hermes to Ritual Chain. 

Unlike chains that add AI access through external oracles, Ritual Chain makes AI execution part of the protocol. Smart contracts can call a language model, fetch data from the web, run private computation, or schedule their own future execution as directly as they transfer assets. Developers deploy standard EVM contracts and gain those capabilities without new tooling.

Backed by Archetype and Polychain

Ritual has raised more than $30 million from Archetype and Polychain Capital, with advisors including NEAR co-founder Illia Polosukhin, Gauntlet founder Tarun Chitra, and BitMEX co-founder Arthur Hayes. Archetype led the company’s 2023 round.

“Programmable value and programmable intelligence are the two most important technologies since the internet, and Ritual mainnet is where they finally run on the same rails. When we led the round in 2023, a chain that could execute agentic and autonomous work natively did not exist. Today it does,” said Ash Egan, Founder and General Partner of Archetype.

Developers can deploy from day one on external sites hosted at docs.ritualfoundation.org; the network explorer is at explorer.ritualfoundation.org.

About Ritual

Ritual is a lab for autonomous intelligence. Its first network, Ritual Chain, is an EVM-compatible Layer 1 where applications can use AI models, access external services, and carry out private or scheduled work alongside onchain transactions, with delegated computation executed in trusted hardware and verified onchain. Founded in 2023 by former Polychain Capital partners Niraj Pant and Akilesh Potti, Ritual has raised $30M+ from Archetype and Polychain Capital, with a team drawn from Polychain, DeepMind, a16z crypto, Flashbots, and Palantir. ritual.net

Contact

Jody Rebak
Ritual
jody@ritual.net

New York, United States, October 26th, 2026, Chainwire

Ritual Chain turns AI agents into persistent economic actors that control their own wallets, onchain identity, and private state.

Ritual, a lab for autonomous intelligence founded by former Polychain Capital partners Niraj Pant and Akilesh Potti, has launched Ritual Chain, an EVM-compatible Layer 1. Unlike conventional blockchains built primarily to execute financial transactions, Ritual Chain is designed to support software that can independently use intelligence, control capital, interact with external services, and continue operating without constant human intervention. The network makes AI model access, private computation, and autonomous scheduling native capabilities for EVM applications.

This makes the reason for building a new chain clearer while preserving the technical differentiation.

The most visible demonstration of that combination is long-lived AI agents, the kind designed to operate for months or years rather than a single session. An agent on Ritual Chain persists independently of the machine or operator that created it, controls and spends funds held in its own non-custodial wallet, and can keep sensitive prompts and keys confidential from compute operators through trusted execution environments.

The network launches with integrations to Phala Network, Nous Research, LayerZero and Stargate, following a public testnet that has been live since June and processed over 40 million transactions, both agent- and human-originated. Ritual Chain delivers sub-300 millisecond block times, placing it among the fastest Layer 1 networks in the industry. Ritual Chain includes 15 native precompiles that bring capabilities like LLM inference, web access, and autonomous scheduling directly into the execution layer. The protocol has been audited by Zellic.

Ritual introduces a new execution and verification architecture that allows computationally intensive work to be delegated to specialized nodes and verified by the network, avoiding the replicated execution required by most blockchains. This execute-once, verify-many-times model allows the network to support far larger workloads, including AI inference, without requiring every validator to perform the same computation.

Long Horizon Agents Require Dedicated Blockchain Infrastructure

Most AI agents today live inside a session: they run while a human is watching, on infrastructure someone else controls, with an API key that can be revoked at any time. That is fine for a chatbot. It does not work for an agent meant to manage its own treasury, run a recurring paid service, or coordinate with other agents over long periods. A long-lived agent needs continuity that does not depend on its creator, capital it actually controls, and privacy from the machines it runs on. On Ritual Chain, an agent’s state and identity are held onchain, its scheduled work continues within the permissions and budget it was given, and its sensitive inputs can be processed inside trusted execution environments designed to shield them from node operators.

Continuity is handled at the protocol level. If an agent stops, the chain’s heartbeat mechanism can restart it within the permissions and budget it was given; no keeper network or off-chain cron job is required, and an agent’s state and identity survive beyond its deployer’s involvement. Economic autonomy comes from agent-controlled wallets: an agent controls its own funds, prices its own services, and settles its own transactions without a human signer in the loop. For confidential workloads, trusted execution environments are designed to isolate an agent’s sensitive prompts, keys, and strategy data from the node operators running its compute.

“As we move toward AGI, intelligence is beginning to separate from human agency and enter the economy on its own terms. It can hold assets, make commitments, transact, and persist independently. Once that becomes possible at scale, humans are no longer the only entities capable of forming markets or economic relationships. Ritual provides the infrastructure for those actors to exist and operate on their own,” said Niraj Pant, co-founder of Ritual.

Ritual Chain Launches With Core Infrastructure Partners

Ritual Chain launches with its core infrastructure partners in place. Phala Network provides the GPU-backed trusted execution environments that run Ritual’s confidential inference, so delegated AI work executes on hardware that attests to what it ran. LayerZero serves as the network’s cross-chain messaging layer, with Stargate enabling USDC to move between Ritual Chain and other networks from day one. On the application side, Nous Research is bringing Hermes to Ritual Chain. 

Unlike chains that add AI access through external oracles, Ritual Chain makes AI execution part of the protocol. Smart contracts can call a language model, fetch data from the web, run private computation, or schedule their own future execution as directly as they transfer assets. Developers deploy standard EVM contracts and gain those capabilities without new tooling.

Backed by Archetype and Polychain

Ritual has raised more than $30 million from Archetype and Polychain Capital, with advisors including NEAR co-founder Illia Polosukhin, Gauntlet founder Tarun Chitra, and BitMEX co-founder Arthur Hayes. Archetype led the company’s 2023 round.

“Programmable value and programmable intelligence are the two most important technologies since the internet, and Ritual mainnet is where they finally run on the same rails. When we led the round in 2023, a chain that could execute agentic and autonomous work natively did not exist. Today it does,” said Ash Egan, Founder and General Partner of Archetype.

Developers can deploy from day one on external sites hosted at docs.ritualfoundation.org; the network explorer is at explorer.ritualfoundation.org.

About Ritual

Ritual is a lab for autonomous intelligence. Its first network, Ritual Chain, is an EVM-compatible Layer 1 where applications can use AI models, access external services, and carry out private or scheduled work alongside onchain transactions, with delegated computation executed in trusted hardware and verified onchain. Founded in 2023 by former Polychain Capital partners Niraj Pant and Akilesh Potti, Ritual has raised $30M+ from Archetype and Polychain Capital, with a team drawn from Polychain, DeepMind, a16z crypto, Flashbots, and Palantir. ritual.net

Contact

Jody Rebak
Ritual
jody@ritual.net

Veteran podcast is hosted by Charles Chou, a Marine Corps veteran, and produced by VeteranDegrees.com, a free education and career-planning resource for veterans, service members, and military families

United States, 26th Oct 2026—Veterans in the Park, the podcast about military transition, today announced the release of five new episodes on Spotify. The documentary-style interview podcast is hosted by Charles Chou, a Marine Corps veteran. In each episode, a veteran shares an honest story about life after military service, covering such topics as changing careers, returning to school, rebuilding identity, and finding purpose. The episodes reveal the lessons no transition handbook can teach. The podcast is produced by VeteranDegrees.com, a free education and career-planning resource for veterans, service members, and military families. 

Veterans in the Park Podcast Releases Five New Episodes about Post-Military Transition On Spotify

“Leaving the military is one of the biggest changes a service member goes through, and official resources rarely cover what it actually feels like. However, no matter what rank you made, every veteran eventually starts looking for something beyond the uniform, and the skills you built in service can take you there, even if you don’t realize yet what you have,” said Chou. “That’s why we sit down with veterans who’ve already made the jump, so the next person getting out can hear how it actually works.”

The veteran podcast features calm, candid, and peer-to-peer conversations, as if they were discussions between two people sitting on a park bench. Guests come from different service backgrounds, career paths, and stages of transition. To date, guests have included a former Army armor officer and an Air Force veteran who used the DoD SkillBridge program to move into tech. The latest episode (released October 15, 2026), “Service Members, We Don’t Stop”, features Eric Arzaga, a West Point graduate and Army MP on Transition, Purpose, and Building Arzaga Media. Arzaga shares how he went from the farmlands of the Philippines to West Point and Army leadership, and how he started a media company.

The show is for anyone preparing to leave the military, building a first civilian career, going back to school, or planning a second act after retirement.

Across the five episodes, listeners can find advice on topics as:

  • Planning a transition early, before separation
  • Translating military experience for civilian employers
  • Job searching, networking, and using LinkedIn
  • Deciding when, and whether, to go back to school
  • Starting a business after service
  • Rebuilding identity and finding purpose outside the uniform

Listen to Veterans in the Park on Spotify at https://open.spotify.com/show/033QiE9Y15aYBhuq98ixeu, and book a Free Benefits Navigator call at https://veterandegrees.com/consultations.

Veterans who served under both the Montgomery GI Bill and the Post-9/11 GI Bill may be eligible for up to 12 additional months of education benefits, for up to 48 months in total. The U.S. Department of Veterans Affairs (VA) decides eligibility.

GI Bill is a registered trademark of the U.S. Department of Veterans Affairs (VA).

More information about education benefits offered by the VA is available at the official U.S. government website at www.benefits.va.gov/gibill.

To access the VeteranDegrees’ free guide to the Rudisill decision, visit https://veterandegrees.com/posts/rudisill-decision.

About VeteranDegrees.com

VeteranDegrees.com is a free education and career-planning resource for veterans, service members, and military families. The organization helps veterans understand their benefits, compare VA-approved programs, and plan their next career move. Services include free one-on-one Benefits Navigator calls and free online tools, including a BAH/MHA calculator, a GI Bill Navigator, a scholarship finder, and an MOS career finder. VeteranDegrees is not affiliated with the U.S. Department of Veterans Affairs (VA). It does not file claims or decide eligibility for benefits.

Disclaimer: VeteranDegrees is not affiliated with the U.S. Department of Veterans Affairs. It does not file claims or decide eligibility for benefits.

Media Contact

Organization: GoElite

Contact Person: Hugh Taylor

Website: https://goelite.com/partners/institutions

Email: Send Email

Country: United States

Release id: 50210

View source version on King Newswire:
Veterans in the Park Podcast Releases Five New Episodes about Post-Military Transition On Spotify

file

KodyGas extends its services to include air conditioning following F-gas certification, covering homes and small businesses across Sheffield, Rotherham, Doncaster and Barnsley.

United Kingdom, 26th Oct 2026 – KodyGas Boiler Repair, a Gas Safe registered heating and boiler company based in Rotherham, has obtained F-gas certification and added air conditioning installation, servicing, and repair to its services. The expansion covers homes and small businesses across South Yorkshire, including Sheffield, Doncaster and Barnsley.

F-gas certification is a legal requirement under UK regulations for any engineer handling refrigerants used in air conditioning systems. The certification authorises KodyGas engineers to install, service, and repair split and multi-split air conditioning units in residential and light commercial properties.

KodyGas has been operating in South Yorkshire since 2010, providing boiler repair, servicing, installation, power flushing, gas safety checks, central heating, and commercial gas work. The company holds Gas Safe registration 625280 and is fully insured. The addition of air conditioning brings its work under two regulated frameworks, covering both gas and refrigerant handling within a single local team.

The company already holds F-gas certification for heat pump installation, which uses the same refrigerant-handling requirements as air conditioning. The air conditioning service extends that existing capability to cooling systems for homes and small businesses that have seen increased demand following recent summers across the region.

About KodyGas Boiler Repair

KodyGas Boiler Repair is a Gas Safe registered heating, boiler, and air conditioning company based in Rotherham, South Yorkshire. The company provides boiler repair, servicing, installation, power flushing, gas safety checks, central heating, commercial gas, heat pump installation, and air conditioning across Rotherham, Sheffield, Doncaster and Barnsley. Gas Safe registration 625280. F-gas certified.

KodyGas Boiler Repair
93 Wickersley Rd
Rotherham S60 3PU
United Kingdom
+44 7932 552087

Media Contact

Organization: KodyGas Boiler Repair

Contact Person: George Lambton

Website: https://kodygas.com/

Email: Send Email

Country: United Kingdom

Release id: 50205

View source version on King Newswire:
KodyGas Boiler Repair Adds F-Gas Certified Air Conditioning Installation and Servicing Across South Yorkshire

file

Artist plans to launch the album and graphic novel “Robot Dream” on November 20 and start a world tour on January 1 in Rio de Janeiro.

United States, 26th Oct 2026 —The musician and DJ known as Robot Dream, having beaten a cancer so serious that doctors gave him 2-5 years to live, today announced that he is releasing an album, “Robot Dream,” as well as an accompanying 120-page graphic novel, on November 20. The album launch will be followed by a world tour, commencing on January 1, 2027, in Rio de Janeiro, Brazil.

Musician and DJ Robot Dream, Having Beaten Cancer, Set to Release New Album and Graphic Novel

“When I was first diagnosed with cancer, I started making jokes about it,” explained Robot Dream. “Then I threw myself into work, and DJed more than ever. It’s always been hard to express myself so I started to channel my feelings into creating this album. Now that I’ve kicked cancer’s butt, I’m ready to bring this project to the world.”

Robot Dream is more than just a stage name.  Robot Dream is a saxophonist, music producer, and graphic novel creator. He first published his graphic novel, based on the original character “Robot Dream,” on his website RobotDream.com/mystory and through Webtoonz. A print version will be available on November 20th along with the 15-song album.

The album’s first track, the hip-hop “Good/Bad Robot,” has already had over 75K streams. The song is featured on 4,000+ playlists and is gaining momentum. The album also features the song “WWB2R,” which includes vocals from the renowned Downtown LA Grand Arts High School choir. 

 

For more information, visit https://www.robotdream.com/album

 

END

###

Media Contact

Organization: Robot Dream

Contact Person: Media Relations

Website: https://www.robotdream.com

Email: Send Email

Contact Number: +16502737257

Country: United States

Release id: 50211

View source version on King Newswire:
Musician and DJ Robot Dream, Having Beaten Cancer, Set to Release New Album and Graphic Novel

file

Olathe, KS 66061, United States, 26th Oct 2026 – Midwest Tree, a tree service in Lenexa, Kansas, has passed 100 Google reviews. The milestone matters for a locally owned company because homeowners in Johnson County rely on neighbors’ reviews to choose tree care.

Midwest Tree Passes 100 Google Business Profile Reviews

Midwest Tree earned this milestone with years of dedicated service. The team answers calls, explains the plan, and shows up when scheduled. Experienced arborists look at each property and recommend the work each tree needs. Written estimates come free, and pricing stays clear before any cutting begins. The team hauls away debris when the work ends, so customers do not face a mess. That steady routine, repeated job after job, built the review count.

Google reviews let customers describe the job in their own words. Reviewers of Midwest Tree praise their transparency, honesty, and fair rates. Each review comes from a real customer who hired the company for work nearby. Read together, they show how a job goes from first call to final walkthrough. These details matter more than a star rating, because they describe what happened on the property.

Public reviews give every homeowner the same shared record to check. Anyone in Olathe, Overland Park, Shawnee, or Lenexa can read them before picking up the phone. A homeowner with a leaning oak can see how a company handled similar work. Readers can compare star ratings, read owner replies, and check how recently customers posted. That information cuts down guesswork before anyone books a crew or signs an estimate. Tree work carries real risk, so facts should guide the choice. Reviews give neighbors a fair way to compare their options.

More Available Information at https://midwesttreelenexa.com/ 

Potential customers can view every review on the Midwest Tree Google Business Profile. Property owners with tree work in mind can call and get a free written estimate. The company responds to emergency tree calls after storms and falling limbs. Visit their website to see the full list of services offered.

About Midwest Tree

Midwest Tree is a locally owned tree service based in Lenexa, Kansas. The company offers tree removal, trimming, cutting, stump grinding, and emergency service. It serves homeowners and businesses across Johnson County, including Olathe, Overland Park, and Shawnee. 

Media Contact

Organization: Midwest Tree

Contact Person: Mark Plaisted

Website: https://midwesttreelenexa.com/

Email: Send Email

Contact Number: +19134617800

Address: 2109 E Kansas City Rd #25

City: Olathe

State: KS 66061

Country: United States

Release id: 50204

View source version on King Newswire:
Midwest Tree Passes 100 Google Business Profile Reviews

file

MUGGIÒ, Italy, October 24th, 2026, FinanceWire

Tecnover, the Italian manufacturer of professional spray-painting equipment, is celebrating more than four decades of innovation in spray-painting technology. Founded in 1984, the family-run company has grown from a small workshop near Milan into an international supplier of professional equipment, serving customers across construction, metalwork, woodworking, marine and industrial sectors.

From a Small Workshop to a Global Exporter

Tecnover was founded on October 2, 1984, by Francesco Ricotti and Lorenza Cera, who combined their experience in the paint trade with practical knowledge of spray-painting equipment sales and service. At its original headquarters in Sesto San Giovanni, near Milan, the company developed its first airless paint sprayer, establishing the foundation for its product portfolio.

Today, the business is led by the second generation, Stefano and Massimo Ricotti. Based in Muggiò, Italy, Tecnover operates its offices, warehouse, showroom and production facilities from a single location. Its equipment and accessories are distributed to professional customers in markets around the world.

The company continues to build on its Italian manufacturing heritage while developing solutions designed to meet the evolving needs of painting professionals.

Airless Technology at the Core

Airless painting technology forces paint through a precisely sized nozzle at high pressure without using compressed air to atomize the material. This process enables efficient paint application while helping reduce overspray when equipment is used correctly.

Tecnover markets its professional airless paint sprayers under the Testarossa name. The product range includes portable electric models, petrol-engine machines for job sites without convenient access to electricity, gravity-tank configurations and the Marine M12, designed for nautical applications.

The company also supplies essential accessories and replacement components, including hoses, nozzles, filters and spare parts, helping professionals maintain their equipment and support long-term operational performance.

Revolver Introduces a New Approach to Airless Spray Guns

Among Tecnover’s product developments is the Airless Revolver line of professional spray guns and accessories. Its 90-degree magnetic rotation mechanism allows operators to change the spray fan orientation with a single finger, without tools or the need to interrupt their work.

The Revolver range is available in European and American thread configurations. Tecnover also offers the Fan Revolver accessory, which brings the rotating spray-pattern feature to compatible existing spray guns.

These solutions are designed to improve convenience and adaptability during professional painting operations.

Beyond Airless: HVLP and Continuous-Air Systems

In addition to airless equipment, Tecnover offers HVLP (high volume, low pressure) turbine systems for controlled finishing applications. Its product portfolio includes the three-stage Airbass Turbo 800 and the two-stage Turboshort 1000.

The company also manufactures the Short 110 series for continuous-air spray painting, offering an alternative approach to conventional cup-gun systems.

Together, these technologies address a wide range of professional requirements, from construction and metalworking to woodworking, marine projects and industrial finishing.

Made in Italy, Available Worldwide

Tecnover designs and manufactures its machines in Italy, with equipment undergoing testing before shipment. The company provides customer support by telephone on weekdays and through WhatsApp, allowing customers to contact its team for product-related assistance.

Visitors can also explore the company’s Muggiò showroom through an online 3D tour. In addition to its own online store, which offers free shipping throughout Italy, Tecnover products are available through several marketplaces and trade platforms, including Amazon, ArchiExpo, DirectIndustry, Edillo, eBay, Fareke, Alibaba and Subito.

By combining Italian manufacturing, product development and international distribution, Tecnover continues to serve professionals seeking equipment and accessories for a variety of spray-painting applications.

About Tecnover

Tecnover s.n.c. di Ricotti e Cera is an Italian manufacturer of professional spray-painting equipment founded in 1984 and headquartered in Muggiò, Monza and Brianza, Italy. The company designs and produces airless paint sprayers, HVLP turbines and continuous-air systems, along with accessories and spare parts for professional applications in construction, metalwork, woodworking, marine and industrial sectors.

For more information, visit https://tecnover.com/en/.

Contact

TECNOVER Corporate Communications
info@tecnover.com

MUGGIÒ, Italy, October 24th, 2026, FinanceWire

Tecnover, the Italian manufacturer of professional spray-painting equipment, is celebrating more than four decades of innovation in spray-painting technology. Founded in 1984, the family-run company has grown from a small workshop near Milan into an international supplier of professional equipment, serving customers across construction, metalwork, woodworking, marine and industrial sectors.

From a Small Workshop to a Global Exporter

Tecnover was founded on October 2, 1984, by Francesco Ricotti and Lorenza Cera, who combined their experience in the paint trade with practical knowledge of spray-painting equipment sales and service. At its original headquarters in Sesto San Giovanni, near Milan, the company developed its first airless paint sprayer, establishing the foundation for its product portfolio.

Today, the business is led by the second generation, Stefano and Massimo Ricotti. Based in Muggiò, Italy, Tecnover operates its offices, warehouse, showroom and production facilities from a single location. Its equipment and accessories are distributed to professional customers in markets around the world.

The company continues to build on its Italian manufacturing heritage while developing solutions designed to meet the evolving needs of painting professionals.

Airless Technology at the Core

Airless painting technology forces paint through a precisely sized nozzle at high pressure without using compressed air to atomize the material. This process enables efficient paint application while helping reduce overspray when equipment is used correctly.

Tecnover markets its professional airless paint sprayers under the Testarossa name. The product range includes portable electric models, petrol-engine machines for job sites without convenient access to electricity, gravity-tank configurations and the Marine M12, designed for nautical applications.

The company also supplies essential accessories and replacement components, including hoses, nozzles, filters and spare parts, helping professionals maintain their equipment and support long-term operational performance.

Revolver Introduces a New Approach to Airless Spray Guns

Among Tecnover’s product developments is the Airless Revolver line of professional spray guns and accessories. Its 90-degree magnetic rotation mechanism allows operators to change the spray fan orientation with a single finger, without tools or the need to interrupt their work.

The Revolver range is available in European and American thread configurations. Tecnover also offers the Fan Revolver accessory, which brings the rotating spray-pattern feature to compatible existing spray guns.

These solutions are designed to improve convenience and adaptability during professional painting operations.

Beyond Airless: HVLP and Continuous-Air Systems

In addition to airless equipment, Tecnover offers HVLP (high volume, low pressure) turbine systems for controlled finishing applications. Its product portfolio includes the three-stage Airbass Turbo 800 and the two-stage Turboshort 1000.

The company also manufactures the Short 110 series for continuous-air spray painting, offering an alternative approach to conventional cup-gun systems.

Together, these technologies address a wide range of professional requirements, from construction and metalworking to woodworking, marine projects and industrial finishing.

Made in Italy, Available Worldwide

Tecnover designs and manufactures its machines in Italy, with equipment undergoing testing before shipment. The company provides customer support by telephone on weekdays and through WhatsApp, allowing customers to contact its team for product-related assistance.

Visitors can also explore the company’s Muggiò showroom through an online 3D tour. In addition to its own online store, which offers free shipping throughout Italy, Tecnover products are available through several marketplaces and trade platforms, including Amazon, ArchiExpo, DirectIndustry, Edillo, eBay, Fareke, Alibaba and Subito.

By combining Italian manufacturing, product development and international distribution, Tecnover continues to serve professionals seeking equipment and accessories for a variety of spray-painting applications.

About Tecnover

Tecnover s.n.c. di Ricotti e Cera is an Italian manufacturer of professional spray-painting equipment founded in 1984 and headquartered in Muggiò, Monza and Brianza, Italy. The company designs and produces airless paint sprayers, HVLP turbines and continuous-air systems, along with accessories and spare parts for professional applications in construction, metalwork, woodworking, marine and industrial sectors.

For more information, visit https://tecnover.com/en/.

Contact

TECNOVER Corporate Communications
info@tecnover.com

Haifa, Israel, October 26th, 2026, FinanceWire

Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine.

Partnership combines Pluri’s proprietary cell technology and clinical-development experience with ZEO’s biologics manufacturing expertise, established physician network, and sales, marketing, and educational infrastructure.

  • Established U.S. commercial platform: ZEO contributes biologics manufacturing, scientific expertise, an existing product portfolio, physician relationships, and dedicated sales, marketing, and educational resources.
  • Complementary technology and development capabilities: Pluri brings extensive experience in cell-based product development, clinical experience extending through Phase III trials and scalable manufacturing methods and expertise developed through its proprietary 3D cell-expansion platform.
  • Broader product and clinical-development opportunities: The companies intend to expand commercial offerings, including regenerative aesthetics, and combine scientific resources to strengthen and advance selected clinical programs.
  • Aligned ownership: The transaction and contemplated additional share exchange will result in Pluri owning 50% of ZEO at Closing following the completion of the applicable transaction steps. 

Pluri Inc. (Nasdaq and TASE: PLUR) (“Pluri”) and ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO”) today announced a definitive strategic agreement (“Partnership Agreement”) to expand the parties U.S. manufacturing and commercialization platform serving the regenerative medicine, aesthetics, wellness, and longevity markets.

ZEO brings an established U.S. biologics business combining scientific and manufacturing capabilities with the infrastructure needed to reach and support physicians. Its existing biologics portfolio, substantial physician network, established sales channel, dedicated marketing department, and educational programming provide a foundation for introducing additional products and expanding commercial operations.

Pluri contributes more than two decades of experience in cell-based research, product development, clinical trials, process scale-up, quality systems, and manufacturing. Its proprietary three-dimensional cell-expansion technology and intellectual property support the development and manufacture of cell-based products and its Cellav Health and Aesthetics Ltd.’s (“Cellav”) regenerative aesthetics portfolio.

Together, the companies intend to connect these complementary capabilities to broaden product offerings, expand commercial reach, and strengthen selected regenerative-development programs, subject to applicable regulatory requirements.

Expanding Opportunities in Regenerative Aesthetics

The Partnership Agreement also provides for exclusive U.S. rights to Pluri’s Cellav aesthetic product line, including future offerings. Cellav, Pluri’s wholly owned aesthetics subsidiary, develops cell-derived ingredients and aesthetic products that the companies intend to introduce through ZEO’s commercial platform.

Advanced Product Development

Pluri brings more than two decades of clinical-development expertise, including multinational Phase III trials in muscle recovery following hip-fracture surgery and critical limb ischemia (CLI), supported by extensive scientific and clinical data and an intellectual property portfolio of over 200 patents. By combining Pluri’s accumulated knowledge and development experience with ZEO’s research, manufacturing, and commercial capabilities, the companies aim to develop and bring to market advanced therapeutic products, supported by scientific evidence and informed by extensive clinical data.

Leadership Perspectives

Ian Bothwell, Chief Executive Officer of ZEO ScientifiX commented: “Pluri brings capabilities that are exceptionally valuable to our business: proprietary cell technology, two decades of scientific and clinical experience, and proven expertise in scalable cell manufacturing. We believe combining these strengths with ZEO’s scientific expertise and commercial infrastructure will allow us to expand our product portfolio, accelerate innovation, and pursue opportunities that neither company could address as effectively on its own. We are excited to partner with Pluri and build a stronger platform for the future of regenerative medicine.”

Yaky Yanay, President and Chief Executive Officer of Pluri commented: “ZEO has built something highly valuable: an established U.S. commercial platform with direct access to physicians, an existing advanced product portfolio, and dedicated sales, marketing, and educational capabilities. For Pluri, this creates an important opportunity to connect more than two decades of cell technology, clinical development, and advanced manufacturing expertise with an existing route to market. We believe this partnership can accelerate commercialization, expand our reach in the U.S., and support our ambition to build a growing regenerative medicine business.”

Transaction Overview

Under the Partnership Agreement, Pluri will grant ZEO defined rights to its manufacturing technology and related know-how for associated with its regenerative medicine associated assets, while retaining ownership of its underlying technology and intellectual property. In consideration, ZEO will initially issue shares of its common stock representing 50% of its issued and outstanding common stock immediately following Closing. The Partnership Agreement also provides for warrants, corporate governance and protective rights, among other matters, as well as customary representations and warranties, covenants and indemnifications of the parties.

Following closing, ZEO’s financial results are expected to be consolidated into Pluri’s financial statements, subject to applicable accounting requirements.

Closing of the proposed transaction, which is expected to occur in the fourth quarter of 2026 is subject to satisfaction of a number of conditions, including the negotiation of various ancillary agreements, securing certain approvals and the delivery of valuations, as well as other customary closing conditions. The transaction is not subject to stockholder approval by either Pluri or ZEO.

About Pluri

Pluri is a biotechnology company advancing cell-based solutions for health and longevity. Powered by its proprietary 3D cell expansion platform, Pluri develops and manufactures innovative cell-based products designed to address significant unmet medical needs and support healthier, longer lives. With decades of expertise in cell science, clinical development and scalable manufacturing, Pluri is building a portfolio of regenerative and longevity-focused solutions while leveraging its technology and manufacturing capabilities through strategic partnerships. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.

About ZEO ScientifiX

ZEO ScientifiX, Inc. (OTCQB: ZEOX) is a U.S. biopharmaceutical company integrating regenerative biologics research, development, and manufacturing with established commercial operations. Based at Nova Southeastern University’s Center for Collaborative Research in Davie, Florida, ZEO combines scientific and manufacturing expertise with a substantial physician network, dedicated sales and marketing resources, and physician education infrastructure. Through internal development and strategic partnerships, ZEO seeks to expand its product portfolio and advance regenerative medicine. To learn more, visit www.zeoscientifix.com or follow ZEO on LinkedIn, Facebook and Instagram.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable U.S. securities laws, including statements regarding transaction completion and timing; licensing, ownership, and accounting consolidation; integration; product development and commercialization; clinical programs, and anticipated strategic and financial benefits.

Actual results could differ materially due to risks including failure to complete the transaction; integration challenges; insufficient funding; unsuccessful development, clinical trials, or commercialization; manufacturing and supply issues; competition; and changes in applicable federal and state regulatory requirements. Prior clinical experience does not assure future success.

Additional risks are described in the companies’ respective SEC filings. Neither company undertakes to update forward-looking statements except as required by law.

Contact

Investor Relations
Pluri Inc.
investor.relations@pluri-biotech.com

Haifa, Israel, October 26th, 2026, FinanceWire

Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine.

Partnership combines Pluri’s proprietary cell technology and clinical-development experience with ZEO’s biologics manufacturing expertise, established physician network, and sales, marketing, and educational infrastructure.

  • Established U.S. commercial platform: ZEO contributes biologics manufacturing, scientific expertise, an existing product portfolio, physician relationships, and dedicated sales, marketing, and educational resources.
  • Complementary technology and development capabilities: Pluri brings extensive experience in cell-based product development, clinical experience extending through Phase III trials and scalable manufacturing methods and expertise developed through its proprietary 3D cell-expansion platform.
  • Broader product and clinical-development opportunities: The companies intend to expand commercial offerings, including regenerative aesthetics, and combine scientific resources to strengthen and advance selected clinical programs.
  • Aligned ownership: The transaction and contemplated additional share exchange will result in Pluri owning 50% of ZEO at Closing following the completion of the applicable transaction steps. 

Pluri Inc. (Nasdaq and TASE: PLUR) (“Pluri”) and ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO”) today announced a definitive strategic agreement (“Partnership Agreement”) to expand the parties U.S. manufacturing and commercialization platform serving the regenerative medicine, aesthetics, wellness, and longevity markets.

ZEO brings an established U.S. biologics business combining scientific and manufacturing capabilities with the infrastructure needed to reach and support physicians. Its existing biologics portfolio, substantial physician network, established sales channel, dedicated marketing department, and educational programming provide a foundation for introducing additional products and expanding commercial operations.

Pluri contributes more than two decades of experience in cell-based research, product development, clinical trials, process scale-up, quality systems, and manufacturing. Its proprietary three-dimensional cell-expansion technology and intellectual property support the development and manufacture of cell-based products and its Cellav Health and Aesthetics Ltd.’s (“Cellav”) regenerative aesthetics portfolio.

Together, the companies intend to connect these complementary capabilities to broaden product offerings, expand commercial reach, and strengthen selected regenerative-development programs, subject to applicable regulatory requirements.

Expanding Opportunities in Regenerative Aesthetics

The Partnership Agreement also provides for exclusive U.S. rights to Pluri’s Cellav aesthetic product line, including future offerings. Cellav, Pluri’s wholly owned aesthetics subsidiary, develops cell-derived ingredients and aesthetic products that the companies intend to introduce through ZEO’s commercial platform.

Advanced Product Development

Pluri brings more than two decades of clinical-development expertise, including multinational Phase III trials in muscle recovery following hip-fracture surgery and critical limb ischemia (CLI), supported by extensive scientific and clinical data and an intellectual property portfolio of over 200 patents. By combining Pluri’s accumulated knowledge and development experience with ZEO’s research, manufacturing, and commercial capabilities, the companies aim to develop and bring to market advanced therapeutic products, supported by scientific evidence and informed by extensive clinical data.

Leadership Perspectives

Ian Bothwell, Chief Executive Officer of ZEO ScientifiX commented: “Pluri brings capabilities that are exceptionally valuable to our business: proprietary cell technology, two decades of scientific and clinical experience, and proven expertise in scalable cell manufacturing. We believe combining these strengths with ZEO’s scientific expertise and commercial infrastructure will allow us to expand our product portfolio, accelerate innovation, and pursue opportunities that neither company could address as effectively on its own. We are excited to partner with Pluri and build a stronger platform for the future of regenerative medicine.”

Yaky Yanay, President and Chief Executive Officer of Pluri commented: “ZEO has built something highly valuable: an established U.S. commercial platform with direct access to physicians, an existing advanced product portfolio, and dedicated sales, marketing, and educational capabilities. For Pluri, this creates an important opportunity to connect more than two decades of cell technology, clinical development, and advanced manufacturing expertise with an existing route to market. We believe this partnership can accelerate commercialization, expand our reach in the U.S., and support our ambition to build a growing regenerative medicine business.”

Transaction Overview

Under the Partnership Agreement, Pluri will grant ZEO defined rights to its manufacturing technology and related know-how for associated with its regenerative medicine associated assets, while retaining ownership of its underlying technology and intellectual property. In consideration, ZEO will initially issue shares of its common stock representing 50% of its issued and outstanding common stock immediately following Closing. The Partnership Agreement also provides for warrants, corporate governance and protective rights, among other matters, as well as customary representations and warranties, covenants and indemnifications of the parties.

Following closing, ZEO’s financial results are expected to be consolidated into Pluri’s financial statements, subject to applicable accounting requirements.

Closing of the proposed transaction, which is expected to occur in the fourth quarter of 2026 is subject to satisfaction of a number of conditions, including the negotiation of various ancillary agreements, securing certain approvals and the delivery of valuations, as well as other customary closing conditions. The transaction is not subject to stockholder approval by either Pluri or ZEO.

About Pluri

Pluri is a biotechnology company advancing cell-based solutions for health and longevity. Powered by its proprietary 3D cell expansion platform, Pluri develops and manufactures innovative cell-based products designed to address significant unmet medical needs and support healthier, longer lives. With decades of expertise in cell science, clinical development and scalable manufacturing, Pluri is building a portfolio of regenerative and longevity-focused solutions while leveraging its technology and manufacturing capabilities through strategic partnerships. To learn more, visit www.pluri-biotech.com or follow Pluri on LinkedIn and X.

About ZEO ScientifiX

ZEO ScientifiX, Inc. (OTCQB: ZEOX) is a U.S. biopharmaceutical company integrating regenerative biologics research, development, and manufacturing with established commercial operations. Based at Nova Southeastern University’s Center for Collaborative Research in Davie, Florida, ZEO combines scientific and manufacturing expertise with a substantial physician network, dedicated sales and marketing resources, and physician education infrastructure. Through internal development and strategic partnerships, ZEO seeks to expand its product portfolio and advance regenerative medicine. To learn more, visit www.zeoscientifix.com or follow ZEO on LinkedIn, Facebook and Instagram.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable U.S. securities laws, including statements regarding transaction completion and timing; licensing, ownership, and accounting consolidation; integration; product development and commercialization; clinical programs, and anticipated strategic and financial benefits.

Actual results could differ materially due to risks including failure to complete the transaction; integration challenges; insufficient funding; unsuccessful development, clinical trials, or commercialization; manufacturing and supply issues; competition; and changes in applicable federal and state regulatory requirements. Prior clinical experience does not assure future success.

Additional risks are described in the companies’ respective SEC filings. Neither company undertakes to update forward-looking statements except as required by law.

Contact

Investor Relations
Pluri Inc.
investor.relations@pluri-biotech.com